Marquette Asset Management, LLC Chinook Therapeutics, Inc. Transaction History

Marquette Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$18.63 - $27.35 $186,300 - $273,500	-10,000 Reduced 31.25%	22,000 $0
Q3 2022 Oct 06, 2022	SELL	$17.51 - $23.37 $105,060 - $140,220	-6,000 Reduced 15.79%	32,000 $629,000
Q2 2022 Jul 15, 2022	BUY	$12.59 - $18.8 $31,475 - $47,000	2,500 Added 7.04%	38,000 $665,000
Q1 2022 Apr 26, 2022	BUY	$12.02 - $16.69 $195,457 - $271,396	16,261 Added 84.52%	35,500 $581,000
Q2 2021 Jul 19, 2021	SELL	$13.6 - $18.98 $81,600 - $113,880	-6,000 Reduced 23.77%	19,239 $272,000
Q1 2021 Apr 23, 2021	SELL	$14.17 - $19.11 $2.22 Million - $3 Million	-156,797 Reduced 86.14%	25,239 $392,000
Q4 2020 Jan 15, 2021	BUY	$11.9 - $20.91 $2.17 Million - $3.81 Million	182,036 New	182,036 $2.89 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Marquette Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Marquette Asset Management, LLC with notifications on news.